Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose study (NCT03660241) investigated the effect of renal impairment on the pharmacokinetics, safety, and tolerability of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ellen Q., Le, Vu, Winton, Jennifer A., Tripathy, Sakambari, Raje, Sangeeta, Wang, Lisy, Dowty, Martin E., Malhotra, Bimal K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303631/
https://www.ncbi.nlm.nih.gov/pubmed/34637151
http://dx.doi.org/10.1002/jcph.1980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303631/
https://www.ncbi.nlm.nih.gov/pubmed/34637151
http://dx.doi.org/10.1002/jcph.1980

Ejemplares similares